ArticleJAMA network open2021

Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.

P Travis Courtney et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.